nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—BMPR2—pulmonary artery—systemic scleroderma	0.0203	0.0706	CbGeAlD
Ruxolitinib—Tuberculosis—Leflunomide—systemic scleroderma	0.0146	0.0496	CcSEcCtD
Ruxolitinib—Tuberculosis—Mycophenolic acid—systemic scleroderma	0.0139	0.0473	CcSEcCtD
Ruxolitinib—Tuberculosis—Mycophenolate mofetil—systemic scleroderma	0.011	0.0373	CcSEcCtD
Ruxolitinib—BMPR2—artery—systemic scleroderma	0.00754	0.0262	CbGeAlD
Ruxolitinib—Tuberculosis—Prednisone—systemic scleroderma	0.00743	0.0253	CcSEcCtD
Ruxolitinib—Myelosuppression—Azathioprine—systemic scleroderma	0.006	0.0204	CcSEcCtD
Ruxolitinib—BMPR2—blood vessel—systemic scleroderma	0.00587	0.0204	CbGeAlD
Ruxolitinib—PRKG2—smooth muscle tissue—systemic scleroderma	0.00573	0.0199	CbGeAlD
Ruxolitinib—PLK1—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.00521	0.418	CbGdCrCtD
Ruxolitinib—PLK1—skin of body—systemic scleroderma	0.00508	0.0176	CbGeAlD
Ruxolitinib—PRKG2—digestive system—systemic scleroderma	0.00453	0.0157	CbGeAlD
Ruxolitinib—DYRK1A—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00431	0.346	CbGdCrCtD
Ruxolitinib—JAK2—blood vessel—systemic scleroderma	0.00422	0.0147	CbGeAlD
Ruxolitinib—Contusion—Mometasone—systemic scleroderma	0.00421	0.0143	CcSEcCtD
Ruxolitinib—PLK1—digestive system—systemic scleroderma	0.00406	0.0141	CbGeAlD
Ruxolitinib—PRKCE—tendon—systemic scleroderma	0.00402	0.014	CbGeAlD
Ruxolitinib—RPS6KA6—tendon—systemic scleroderma	0.00386	0.0134	CbGeAlD
Ruxolitinib—PRKG2—lung—systemic scleroderma	0.00378	0.0131	CbGeAlD
Ruxolitinib—Herpes zoster—Azathioprine—systemic scleroderma	0.00374	0.0127	CcSEcCtD
Ruxolitinib—JAK3—connective tissue—systemic scleroderma	0.00362	0.0126	CbGeAlD
Ruxolitinib—JAK1—connective tissue—systemic scleroderma	0.0036	0.0125	CbGeAlD
Ruxolitinib—Herpes zoster—Leflunomide—systemic scleroderma	0.00353	0.012	CcSEcCtD
Ruxolitinib—PRKCE—lung—systemic scleroderma	0.00353	0.0123	CbGeAlD
Ruxolitinib—PLK1—lung—systemic scleroderma	0.00339	0.0118	CbGeAlD
Ruxolitinib—RPS6KA6—lung—systemic scleroderma	0.00339	0.0118	CbGeAlD
Ruxolitinib—Herpes zoster—Mycophenolic acid—systemic scleroderma	0.00337	0.0115	CcSEcCtD
Ruxolitinib—HIPK2—connective tissue—systemic scleroderma	0.00336	0.0117	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—systemic scleroderma	0.00329	0.0114	CbGeAlD
Ruxolitinib—JAK1—skin of body—systemic scleroderma	0.00325	0.0113	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—systemic scleroderma	0.0031	0.0108	CbGeAlD
Ruxolitinib—MARK2—digestive system—systemic scleroderma	0.00308	0.0107	CbGeAlD
Ruxolitinib—Contusion—Leflunomide—systemic scleroderma	0.00305	0.0104	CcSEcCtD
Ruxolitinib—Herpes zoster—Lisinopril—systemic scleroderma	0.00303	0.0103	CcSEcCtD
Ruxolitinib—CAMK1—tendon—systemic scleroderma	0.00302	0.0105	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—systemic scleroderma	0.00301	0.0105	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—systemic scleroderma	0.00295	0.0103	CbGeAlD
Ruxolitinib—PLK1—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00295	0.236	CbGdCrCtD
Ruxolitinib—MARK2—tendon—systemic scleroderma	0.00293	0.0102	CbGeAlD
Ruxolitinib—Contusion—Mycophenolic acid—systemic scleroderma	0.00291	0.0099	CcSEcCtD
Ruxolitinib—ROCK1—smooth muscle tissue—systemic scleroderma	0.00284	0.00984	CbGeAlD
Ruxolitinib—PLK3—lung—systemic scleroderma	0.00283	0.00982	CbGeAlD
Ruxolitinib—Bone pain—Leflunomide—systemic scleroderma	0.00277	0.00945	CcSEcCtD
Ruxolitinib—BMPR2—smooth muscle tissue—systemic scleroderma	0.00275	0.00956	CbGeAlD
Ruxolitinib—LTK—lung—systemic scleroderma	0.00273	0.00949	CbGeAlD
Ruxolitinib—BMPR2—skin of body—systemic scleroderma	0.00272	0.00944	CbGeAlD
Ruxolitinib—TAOK2—tendon—systemic scleroderma	0.00271	0.00941	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—systemic scleroderma	0.00269	0.00935	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Mycophenolic acid—systemic scleroderma	0.00268	0.00913	CcSEcCtD
Ruxolitinib—Herpes zoster—Mycophenolate mofetil—systemic scleroderma	0.00266	0.00905	CcSEcCtD
Ruxolitinib—CAMK1—lung—systemic scleroderma	0.00265	0.00919	CbGeAlD
Ruxolitinib—JAK3—digestive system—systemic scleroderma	0.00262	0.00908	CbGeAlD
Ruxolitinib—JAK1—digestive system—systemic scleroderma	0.0026	0.00902	CbGeAlD
Ruxolitinib—DCLK1—digestive system—systemic scleroderma	0.0026	0.00902	CbGeAlD
Ruxolitinib—MARK2—lung—systemic scleroderma	0.00257	0.00892	CbGeAlD
Ruxolitinib—Pancytopenia—Pentoxifylline—systemic scleroderma	0.00254	0.00864	CcSEcCtD
Ruxolitinib—JAK1—tendon—systemic scleroderma	0.00247	0.00859	CbGeAlD
Ruxolitinib—DCLK1—tendon—systemic scleroderma	0.00247	0.00859	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—systemic scleroderma	0.00245	0.00849	CbGeAlD
Ruxolitinib—STK16—digestive system—systemic scleroderma	0.00244	0.00847	CbGeAlD
Ruxolitinib—HIPK2—digestive system—systemic scleroderma	0.00243	0.00843	CbGeAlD
Ruxolitinib—CAMK1D—tendon—systemic scleroderma	0.00241	0.00838	CbGeAlD
Ruxolitinib—PHKG2—tendon—systemic scleroderma	0.0024	0.00833	CbGeAlD
Ruxolitinib—Infestation—Pentoxifylline—systemic scleroderma	0.00238	0.00811	CcSEcCtD
Ruxolitinib—Infestation NOS—Pentoxifylline—systemic scleroderma	0.00238	0.00811	CcSEcCtD
Ruxolitinib—TYK2—connective tissue—systemic scleroderma	0.00238	0.00826	CbGeAlD
Ruxolitinib—TAOK2—lung—systemic scleroderma	0.00238	0.00825	CbGeAlD
Ruxolitinib—DAPK2—tendon—systemic scleroderma	0.00236	0.00819	CbGeAlD
Ruxolitinib—MKNK2—connective tissue—systemic scleroderma	0.00235	0.00815	CbGeAlD
Ruxolitinib—STK16—tendon—systemic scleroderma	0.00232	0.00806	CbGeAlD
Ruxolitinib—HIPK2—tendon—systemic scleroderma	0.00231	0.00802	CbGeAlD
Ruxolitinib—RET—connective tissue—systemic scleroderma	0.00229	0.00795	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Pentoxifylline—systemic scleroderma	0.00225	0.00767	CcSEcCtD
Ruxolitinib—Epistaxis—Pentoxifylline—systemic scleroderma	0.00225	0.00765	CcSEcCtD
Ruxolitinib—ROCK1—digestive system—systemic scleroderma	0.00224	0.00777	CbGeAlD
Ruxolitinib—DAPK3—tendon—systemic scleroderma	0.00222	0.0077	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—systemic scleroderma	0.00222	0.0077	CbGeAlD
Ruxolitinib—CLK2—tendon—systemic scleroderma	0.0022	0.00763	CbGeAlD
Ruxolitinib—JAK3—lung—systemic scleroderma	0.00218	0.00758	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—systemic scleroderma	0.00218	0.00756	CbGeAlD
Ruxolitinib—BMPR2—digestive system—systemic scleroderma	0.00217	0.00755	CbGeAlD
Ruxolitinib—JAK1—lung—systemic scleroderma	0.00217	0.00754	CbGeAlD
Ruxolitinib—DCLK1—lung—systemic scleroderma	0.00217	0.00754	CbGeAlD
Ruxolitinib—JAK2—connective tissue—systemic scleroderma	0.00217	0.00752	CbGeAlD
Ruxolitinib—PLK4—lung—systemic scleroderma	0.00216	0.00749	CbGeAlD
Ruxolitinib—TYK2—skin of body—systemic scleroderma	0.00215	0.00746	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—systemic scleroderma	0.00215	0.00746	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—systemic scleroderma	0.00215	0.00746	CbGeAlD
Ruxolitinib—Haemoglobin—Pentoxifylline—systemic scleroderma	0.00215	0.00732	CcSEcCtD
Ruxolitinib—Haemorrhage—Pentoxifylline—systemic scleroderma	0.00214	0.00728	CcSEcCtD
Ruxolitinib—CAMK1D—lung—systemic scleroderma	0.00212	0.00736	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Mycophenolate mofetil—systemic scleroderma	0.00212	0.00721	CcSEcCtD
Ruxolitinib—PHKG2—lung—systemic scleroderma	0.00211	0.00731	CbGeAlD
Ruxolitinib—Bone pain—Mycophenolate mofetil—systemic scleroderma	0.00209	0.00712	CcSEcCtD
Ruxolitinib—DAPK2—lung—systemic scleroderma	0.00207	0.00719	CbGeAlD
Ruxolitinib—BMPR2—tendon—systemic scleroderma	0.00207	0.00718	CbGeAlD
Ruxolitinib—STK16—lung—systemic scleroderma	0.00204	0.00707	CbGeAlD
Ruxolitinib—HIPK2—lung—systemic scleroderma	0.00203	0.00704	CbGeAlD
Ruxolitinib—Urinary tract infection—Mometasone—systemic scleroderma	0.002	0.0068	CcSEcCtD
Ruxolitinib—MAP3K19—lung—systemic scleroderma	0.00199	0.00689	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—systemic scleroderma	0.00198	0.00688	CbGeAlD
Ruxolitinib—JAK2—skin of body—systemic scleroderma	0.00196	0.00679	CbGeAlD
Ruxolitinib—DAPK3—lung—systemic scleroderma	0.00195	0.00676	CbGeAlD
Ruxolitinib—CAMK2G—digestive system—systemic scleroderma	0.00195	0.00676	CbGeAlD
Ruxolitinib—Epistaxis—Mometasone—systemic scleroderma	0.00194	0.0066	CcSEcCtD
Ruxolitinib—CLK2—lung—systemic scleroderma	0.00193	0.0067	CbGeAlD
Ruxolitinib—Pancytopenia—Captopril—systemic scleroderma	0.00192	0.00655	CcSEcCtD
Ruxolitinib—TAOK3—connective tissue—systemic scleroderma	0.0019	0.00661	CbGeAlD
Ruxolitinib—Neutropenia—Captopril—systemic scleroderma	0.00189	0.00644	CcSEcCtD
Ruxolitinib—MAP3K3—skin of body—systemic scleroderma	0.00188	0.00654	CbGeAlD
Ruxolitinib—ROCK1—lung—systemic scleroderma	0.00187	0.00649	CbGeAlD
Ruxolitinib—BMP2K—tendon—systemic scleroderma	0.00185	0.00643	CbGeAlD
Ruxolitinib—CAMK2G—tendon—systemic scleroderma	0.00185	0.00643	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Mycophenolic acid—systemic scleroderma	0.00184	0.00627	CcSEcCtD
Ruxolitinib—LRRK2—tendon—systemic scleroderma	0.00184	0.00637	CbGeAlD
Ruxolitinib—Flatulence—Pentoxifylline—systemic scleroderma	0.00183	0.00624	CcSEcCtD
Ruxolitinib—Weight decreased—Captopril—systemic scleroderma	0.00183	0.00624	CcSEcCtD
Ruxolitinib—DYRK1A—lung—systemic scleroderma	0.00182	0.00633	CbGeAlD
Ruxolitinib—BMPR2—lung—systemic scleroderma	0.00182	0.0063	CbGeAlD
Ruxolitinib—NUAK2—lung—systemic scleroderma	0.00174	0.00603	CbGeAlD
Ruxolitinib—Anaemia—Pentoxifylline—systemic scleroderma	0.00172	0.00586	CcSEcCtD
Ruxolitinib—TYK2—digestive system—systemic scleroderma	0.00172	0.00597	CbGeAlD
Ruxolitinib—MKNK2—digestive system—systemic scleroderma	0.0017	0.00589	CbGeAlD
Ruxolitinib—Pancytopenia—Azathioprine—systemic scleroderma	0.00168	0.00571	CcSEcCtD
Ruxolitinib—MAP3K7—tendon—systemic scleroderma	0.00167	0.00578	CbGeAlD
Ruxolitinib—RET—digestive system—systemic scleroderma	0.00165	0.00574	CbGeAlD
Ruxolitinib—TYK2—tendon—systemic scleroderma	0.00164	0.00568	CbGeAlD
Ruxolitinib—CAMK2G—lung—systemic scleroderma	0.00163	0.00564	CbGeAlD
Ruxolitinib—BMP2K—lung—systemic scleroderma	0.00163	0.00564	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Mycophenolic acid—systemic scleroderma	0.00162	0.00553	CcSEcCtD
Ruxolitinib—IRAK1—tendon—systemic scleroderma	0.00161	0.00561	CbGeAlD
Ruxolitinib—MKNK2—tendon—systemic scleroderma	0.00161	0.00561	CbGeAlD
Ruxolitinib—LRRK2—lung—systemic scleroderma	0.00161	0.00559	CbGeAlD
Ruxolitinib—Pancytopenia—Leflunomide—systemic scleroderma	0.00158	0.00539	CcSEcCtD
Ruxolitinib—RET—tendon—systemic scleroderma	0.00157	0.00547	CbGeAlD
Ruxolitinib—Infestation—Azathioprine—systemic scleroderma	0.00157	0.00536	CcSEcCtD
Ruxolitinib—Infestation NOS—Azathioprine—systemic scleroderma	0.00157	0.00536	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00157	0.00536	CcSEcCtD
Ruxolitinib—JAK2—digestive system—systemic scleroderma	0.00156	0.00543	CbGeAlD
Ruxolitinib—Neutropenia—Leflunomide—systemic scleroderma	0.00156	0.00531	CcSEcCtD
Ruxolitinib—Contusion—Prednisone—systemic scleroderma	0.00155	0.0053	CcSEcCtD
Ruxolitinib—Pancytopenia—Mycophenolic acid—systemic scleroderma	0.00151	0.00515	CcSEcCtD
Ruxolitinib—Weight decreased—Leflunomide—systemic scleroderma	0.00151	0.00514	CcSEcCtD
Ruxolitinib—Infection—Pentoxifylline—systemic scleroderma	0.00151	0.00514	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—systemic scleroderma	0.00151	0.00513	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Azathioprine—systemic scleroderma	0.00149	0.00507	CcSEcCtD
Ruxolitinib—JAK2—tendon—systemic scleroderma	0.00149	0.00517	CbGeAlD
Ruxolitinib—Neutropenia—Mycophenolic acid—systemic scleroderma	0.00149	0.00507	CcSEcCtD
Ruxolitinib—Infestation—Leflunomide—systemic scleroderma	0.00149	0.00506	CcSEcCtD
Ruxolitinib—Infestation NOS—Leflunomide—systemic scleroderma	0.00149	0.00506	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.00149	0.00506	CcSEcCtD
Ruxolitinib—MAP3K2—lung—systemic scleroderma	0.00148	0.00512	CbGeAlD
Ruxolitinib—Skin disorder—Pentoxifylline—systemic scleroderma	0.00147	0.00502	CcSEcCtD
Ruxolitinib—MAP3K7—lung—systemic scleroderma	0.00146	0.00508	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00495	CcSEcCtD
Ruxolitinib—Weight increased—Mycophenolic acid—systemic scleroderma	0.00145	0.00493	CcSEcCtD
Ruxolitinib—Urinary tract infection—Leflunomide—systemic scleroderma	0.00145	0.00492	CcSEcCtD
Ruxolitinib—Weight decreased—Mycophenolic acid—systemic scleroderma	0.00144	0.0049	CcSEcCtD
Ruxolitinib—TYK2—lung—systemic scleroderma	0.00144	0.00498	CbGeAlD
Ruxolitinib—MAP3K3—tendon—systemic scleroderma	0.00143	0.00498	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Prednisone—systemic scleroderma	0.00143	0.00489	CcSEcCtD
Ruxolitinib—Haemoglobin—Azathioprine—systemic scleroderma	0.00142	0.00484	CcSEcCtD
Ruxolitinib—Infestation—Mycophenolic acid—systemic scleroderma	0.00142	0.00483	CcSEcCtD
Ruxolitinib—Infestation NOS—Mycophenolic acid—systemic scleroderma	0.00142	0.00483	CcSEcCtD
Ruxolitinib—Haematuria—Leflunomide—systemic scleroderma	0.00142	0.00483	CcSEcCtD
Ruxolitinib—IRAK1—lung—systemic scleroderma	0.00142	0.00492	CbGeAlD
Ruxolitinib—MKNK2—lung—systemic scleroderma	0.00142	0.00492	CbGeAlD
Ruxolitinib—Haemorrhage—Azathioprine—systemic scleroderma	0.00141	0.00481	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Leflunomide—systemic scleroderma	0.00141	0.00479	CcSEcCtD
Ruxolitinib—Epistaxis—Leflunomide—systemic scleroderma	0.0014	0.00478	CcSEcCtD
Ruxolitinib—Urinary tract infection—Mycophenolic acid—systemic scleroderma	0.00138	0.0047	CcSEcCtD
Ruxolitinib—TAOK3—digestive system—systemic scleroderma	0.00137	0.00477	CbGeAlD
Ruxolitinib—Pancytopenia—Lisinopril—systemic scleroderma	0.00136	0.00464	CcSEcCtD
Ruxolitinib—Haematuria—Mycophenolic acid—systemic scleroderma	0.00135	0.00461	CcSEcCtD
Ruxolitinib—Haemoglobin—Leflunomide—systemic scleroderma	0.00134	0.00457	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Mycophenolic acid—systemic scleroderma	0.00134	0.00457	CcSEcCtD
Ruxolitinib—Neutropenia—Lisinopril—systemic scleroderma	0.00134	0.00456	CcSEcCtD
Ruxolitinib—Epistaxis—Mycophenolic acid—systemic scleroderma	0.00134	0.00456	CcSEcCtD
Ruxolitinib—Haemorrhage—Leflunomide—systemic scleroderma	0.00133	0.00455	CcSEcCtD
Ruxolitinib—TAOK3—tendon—systemic scleroderma	0.00131	0.00454	CbGeAlD
Ruxolitinib—JAK2—lung—systemic scleroderma	0.00131	0.00453	CbGeAlD
Ruxolitinib—Weight increased—Lisinopril—systemic scleroderma	0.0013	0.00444	CcSEcCtD
Ruxolitinib—Anaemia—Captopril—systemic scleroderma	0.0013	0.00444	CcSEcCtD
Ruxolitinib—Infection—Mometasone—systemic scleroderma	0.0013	0.00443	CcSEcCtD
Ruxolitinib—Weight decreased—Lisinopril—systemic scleroderma	0.0013	0.00442	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00436	CcSEcCtD
Ruxolitinib—Haemoglobin—Mycophenolic acid—systemic scleroderma	0.00128	0.00436	CcSEcCtD
Ruxolitinib—Haemorrhage—Mycophenolic acid—systemic scleroderma	0.00127	0.00434	CcSEcCtD
Ruxolitinib—MAP3K3—lung—systemic scleroderma	0.00126	0.00437	CbGeAlD
Ruxolitinib—Urinary tract infection—Lisinopril—systemic scleroderma	0.00124	0.00423	CcSEcCtD
Ruxolitinib—Haematuria—Lisinopril—systemic scleroderma	0.00122	0.00415	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.00121	0.00412	CcSEcCtD
Ruxolitinib—Epistaxis—Lisinopril—systemic scleroderma	0.00121	0.0041	CcSEcCtD
Ruxolitinib—Body temperature increased—Pentoxifylline—systemic scleroderma	0.0012	0.00409	CcSEcCtD
Ruxolitinib—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00406	CcSEcCtD
Ruxolitinib—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.00117	0.004	CcSEcCtD
Ruxolitinib—Malnutrition—Leflunomide—systemic scleroderma	0.00116	0.00396	CcSEcCtD
Ruxolitinib—TAOK3—lung—systemic scleroderma	0.00115	0.00398	CbGeAlD
Ruxolitinib—Flatulence—Leflunomide—systemic scleroderma	0.00114	0.0039	CcSEcCtD
Ruxolitinib—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00389	CcSEcCtD
Ruxolitinib—Anaemia—Azathioprine—systemic scleroderma	0.00114	0.00387	CcSEcCtD
Ruxolitinib—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00387	CcSEcCtD
Ruxolitinib—Fatigue—Mometasone—systemic scleroderma	0.00113	0.00385	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Captopril—systemic scleroderma	0.00113	0.00384	CcSEcCtD
Ruxolitinib—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00381	CcSEcCtD
Ruxolitinib—Infestation—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00381	CcSEcCtD
Ruxolitinib—Malnutrition—Mycophenolic acid—systemic scleroderma	0.00111	0.00378	CcSEcCtD
Ruxolitinib—Flatulence—Mycophenolic acid—systemic scleroderma	0.00109	0.00372	CcSEcCtD
Ruxolitinib—Asthenia—Pentoxifylline—systemic scleroderma	0.00109	0.00371	CcSEcCtD
Ruxolitinib—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00371	CcSEcCtD
Ruxolitinib—Pruritus—Pentoxifylline—systemic scleroderma	0.00107	0.00366	CcSEcCtD
Ruxolitinib—Anaemia—Leflunomide—systemic scleroderma	0.00107	0.00366	CcSEcCtD
Ruxolitinib—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00364	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00361	CcSEcCtD
Ruxolitinib—Epistaxis—Mycophenolate mofetil—systemic scleroderma	0.00106	0.0036	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00104	0.00354	CcSEcCtD
Ruxolitinib—Body temperature increased—Mometasone—systemic scleroderma	0.00104	0.00353	CcSEcCtD
Ruxolitinib—Anaemia—Mycophenolic acid—systemic scleroderma	0.00102	0.00349	CcSEcCtD
Ruxolitinib—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00344	CcSEcCtD
Ruxolitinib—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.001	0.00342	CcSEcCtD
Ruxolitinib—Dizziness—Pentoxifylline—systemic scleroderma	0.001	0.00342	CcSEcCtD
Ruxolitinib—Malnutrition—Lisinopril—systemic scleroderma	0.000998	0.0034	CcSEcCtD
Ruxolitinib—Infection—Azathioprine—systemic scleroderma	0.000998	0.0034	CcSEcCtD
Ruxolitinib—Fatigue—Captopril—systemic scleroderma	0.000992	0.00338	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—systemic scleroderma	0.000985	0.00335	CcSEcCtD
Ruxolitinib—Flatulence—Lisinopril—systemic scleroderma	0.000984	0.00335	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000983	0.00335	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000982	0.00335	CcSEcCtD
Ruxolitinib—Skin disorder—Azathioprine—systemic scleroderma	0.000975	0.00332	CcSEcCtD
Ruxolitinib—Headache—Pentoxifylline—systemic scleroderma	0.000951	0.00324	CcSEcCtD
Ruxolitinib—Infection—Leflunomide—systemic scleroderma	0.000942	0.00321	CcSEcCtD
Ruxolitinib—Asthenia—Mometasone—systemic scleroderma	0.00094	0.0032	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000937	0.00319	CcSEcCtD
Ruxolitinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.00093	0.00317	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000928	0.00316	CcSEcCtD
Ruxolitinib—Pruritus—Mometasone—systemic scleroderma	0.000927	0.00316	CcSEcCtD
Ruxolitinib—Anaemia—Lisinopril—systemic scleroderma	0.000923	0.00314	CcSEcCtD
Ruxolitinib—Skin disorder—Leflunomide—systemic scleroderma	0.000921	0.00314	CcSEcCtD
Ruxolitinib—Body temperature increased—Captopril—systemic scleroderma	0.00091	0.0031	CcSEcCtD
Ruxolitinib—Infection—Mycophenolic acid—systemic scleroderma	0.000899	0.00306	CcSEcCtD
Ruxolitinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000887	0.00302	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000886	0.00302	CcSEcCtD
Ruxolitinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000879	0.00299	CcSEcCtD
Ruxolitinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000875	0.00298	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000868	0.00296	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000867	0.00295	CcSEcCtD
Ruxolitinib—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000862	0.00294	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000844	0.00288	CcSEcCtD
Ruxolitinib—Asthenia—Captopril—systemic scleroderma	0.000826	0.00281	CcSEcCtD
Ruxolitinib—Headache—Mometasone—systemic scleroderma	0.000821	0.0028	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000819	0.00279	CcSEcCtD
Ruxolitinib—Fatigue—Leflunomide—systemic scleroderma	0.000818	0.00278	CcSEcCtD
Ruxolitinib—Pruritus—Captopril—systemic scleroderma	0.000814	0.00277	CcSEcCtD
Ruxolitinib—Infection—Lisinopril—systemic scleroderma	0.000809	0.00276	CcSEcCtD
Ruxolitinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000809	0.00275	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000798	0.00272	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—systemic scleroderma	0.000796	0.00271	CcSEcCtD
Ruxolitinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000794	0.0027	CcSEcCtD
Ruxolitinib—Skin disorder—Lisinopril—systemic scleroderma	0.000791	0.0027	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000781	0.00266	CcSEcCtD
Ruxolitinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.00078	0.00266	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—systemic scleroderma	0.000774	0.00264	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—systemic scleroderma	0.00077	0.00262	CcSEcCtD
Ruxolitinib—Dizziness—Captopril—systemic scleroderma	0.000761	0.00259	CcSEcCtD
Ruxolitinib—Body temperature increased—Leflunomide—systemic scleroderma	0.00075	0.00255	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00074	0.00252	CcSEcCtD
Ruxolitinib—Headache—Captopril—systemic scleroderma	0.000721	0.00246	CcSEcCtD
Ruxolitinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000715	0.00244	CcSEcCtD
Ruxolitinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000709	0.00242	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000703	0.0024	CcSEcCtD
Ruxolitinib—Fatigue—Lisinopril—systemic scleroderma	0.000703	0.00239	CcSEcCtD
Ruxolitinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.0007	0.00238	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000699	0.00238	CcSEcCtD
Ruxolitinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000693	0.00236	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—systemic scleroderma	0.000685	0.00233	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—systemic scleroderma	0.000681	0.00232	CcSEcCtD
Ruxolitinib—Asthenia—Leflunomide—systemic scleroderma	0.00068	0.00232	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—systemic scleroderma	0.000675	0.0023	CcSEcCtD
Ruxolitinib—Pruritus—Leflunomide—systemic scleroderma	0.000671	0.00229	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—systemic scleroderma	0.000665	0.00227	CcSEcCtD
Ruxolitinib—Dizziness—Azathioprine—systemic scleroderma	0.000664	0.00226	CcSEcCtD
Ruxolitinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000649	0.00221	CcSEcCtD
Ruxolitinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000644	0.00219	CcSEcCtD
Ruxolitinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.00064	0.00218	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—systemic scleroderma	0.000634	0.00216	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—systemic scleroderma	0.000634	0.00216	CcSEcCtD
Ruxolitinib—Headache—Azathioprine—systemic scleroderma	0.000629	0.00214	CcSEcCtD
Ruxolitinib—Dizziness—Leflunomide—systemic scleroderma	0.000627	0.00214	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000616	0.0021	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—systemic scleroderma	0.000605	0.00206	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.0006	0.00204	CcSEcCtD
Ruxolitinib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000598	0.00204	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—systemic scleroderma	0.000598	0.00204	CcSEcCtD
Ruxolitinib—Headache—Leflunomide—systemic scleroderma	0.000594	0.00202	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—systemic scleroderma	0.000593	0.00202	CcSEcCtD
Ruxolitinib—Asthenia—Lisinopril—systemic scleroderma	0.000585	0.00199	CcSEcCtD
Ruxolitinib—Pruritus—Lisinopril—systemic scleroderma	0.000576	0.00196	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—systemic scleroderma	0.000572	0.00195	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—systemic scleroderma	0.000569	0.00194	CcSEcCtD
Ruxolitinib—Headache—Mycophenolic acid—systemic scleroderma	0.000567	0.00193	CcSEcCtD
Ruxolitinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000564	0.00192	CcSEcCtD
Ruxolitinib—Anaemia—Prednisone—systemic scleroderma	0.000548	0.00187	CcSEcCtD
Ruxolitinib—Dizziness—Lisinopril—systemic scleroderma	0.000539	0.00184	CcSEcCtD
Ruxolitinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000512	0.00174	CcSEcCtD
Ruxolitinib—Headache—Lisinopril—systemic scleroderma	0.00051	0.00174	CcSEcCtD
Ruxolitinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000505	0.00172	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000501	0.00171	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—systemic scleroderma	0.000496	0.00169	CcSEcCtD
Ruxolitinib—Infection—Prednisone—systemic scleroderma	0.000481	0.00164	CcSEcCtD
Ruxolitinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000475	0.00162	CcSEcCtD
Ruxolitinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000472	0.00161	CcSEcCtD
Ruxolitinib—Skin disorder—Prednisone—systemic scleroderma	0.00047	0.0016	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—systemic scleroderma	0.000458	0.00156	CcSEcCtD
Ruxolitinib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000447	0.00152	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000419	0.00143	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—systemic scleroderma	0.000417	0.00145	CbGeAlD
Ruxolitinib—Fatigue—Prednisone—systemic scleroderma	0.000417	0.00142	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—systemic scleroderma	0.000402	0.00137	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000397	0.00135	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000396	0.00135	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—systemic scleroderma	0.000393	0.00134	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—systemic scleroderma	0.000383	0.0013	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000349	0.00119	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—systemic scleroderma	0.000349	0.00119	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—systemic scleroderma	0.000347	0.00118	CcSEcCtD
Ruxolitinib—Pruritus—Prednisone—systemic scleroderma	0.000342	0.00117	CcSEcCtD
Ruxolitinib—Dizziness—Prednisone—systemic scleroderma	0.00032	0.00109	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—systemic scleroderma	0.00032	0.00109	CcSEcCtD
Ruxolitinib—Headache—Prednisone—systemic scleroderma	0.000303	0.00103	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—systemic scleroderma	0.00029	0.000988	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—systemic scleroderma	0.000286	0.000975	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—systemic scleroderma	0.000267	0.000911	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—systemic scleroderma	0.000253	0.000863	CcSEcCtD
Ruxolitinib—JAK1—Disease—CSK—systemic scleroderma	0.0001	0.000246	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HSPG2—systemic scleroderma	9.98e-05	0.000246	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SMAD7—systemic scleroderma	9.94e-05	0.000245	CbGpPWpGaD
Ruxolitinib—JAK2—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	9.82e-05	0.000242	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EDN1—systemic scleroderma	9.79e-05	0.000241	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	9.79e-05	0.000241	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD247—systemic scleroderma	9.78e-05	0.000241	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—ITGAM—systemic scleroderma	9.78e-05	0.000241	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SMAD7—systemic scleroderma	9.77e-05	0.000241	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CTLA4—systemic scleroderma	9.73e-05	0.00024	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—MMP1—systemic scleroderma	9.73e-05	0.00024	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—NOS3—systemic scleroderma	9.72e-05	0.000239	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CSK—systemic scleroderma	9.64e-05	0.000238	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	9.64e-05	0.000237	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—RHOB—systemic scleroderma	9.61e-05	0.000237	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFBI—systemic scleroderma	9.58e-05	0.000236	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—TNFAIP3—systemic scleroderma	9.53e-05	0.000235	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CTLA4—systemic scleroderma	9.51e-05	0.000234	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BLK—systemic scleroderma	9.42e-05	0.000232	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD247—systemic scleroderma	9.4e-05	0.000232	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EDN1—systemic scleroderma	9.21e-05	0.000227	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—TNFAIP3—systemic scleroderma	9.16e-05	0.000226	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EDN1—systemic scleroderma	9.15e-05	0.000225	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CTLA4—systemic scleroderma	9.11e-05	0.000224	CbGpPWpGaD
Ruxolitinib—JAK1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	9.05e-05	0.000223	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CTLA4—systemic scleroderma	8.97e-05	0.000221	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—RHOB—systemic scleroderma	8.94e-05	0.00022	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—MMP9—systemic scleroderma	8.8e-05	0.000217	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-DQB1—systemic scleroderma	8.75e-05	0.000216	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—EDN1—systemic scleroderma	8.5e-05	0.00021	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HSPG2—systemic scleroderma	8.43e-05	0.000208	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EDN1—systemic scleroderma	8.33e-05	0.000205	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1A—systemic scleroderma	8.31e-05	0.000205	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD40LG—systemic scleroderma	8.26e-05	0.000204	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CSK—systemic scleroderma	8.23e-05	0.000203	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—NOS3—systemic scleroderma	8.2e-05	0.000202	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CSK—systemic scleroderma	8.14e-05	0.0002	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IRF5—systemic scleroderma	8.1e-05	0.0002	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—MMP9—systemic scleroderma	8.08e-05	0.000199	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TGFB1—systemic scleroderma	8.07e-05	0.000199	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—RHOB—systemic scleroderma	8.02e-05	0.000197	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-DQB1—systemic scleroderma	8.02e-05	0.000197	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—NOS3—systemic scleroderma	8.01e-05	0.000197	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CSK—systemic scleroderma	7.99e-05	0.000197	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—MMP9—systemic scleroderma	7.95e-05	0.000196	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—MMP2—systemic scleroderma	7.94e-05	0.000196	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SMAD7—systemic scleroderma	7.94e-05	0.000196	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRF5—systemic scleroderma	7.86e-05	0.000194	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-DQB1—systemic scleroderma	7.83e-05	0.000193	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CSK—systemic scleroderma	7.75e-05	0.000191	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IRF8—systemic scleroderma	7.74e-05	0.000191	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD247—systemic scleroderma	7.74e-05	0.000191	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ITGAM—systemic scleroderma	7.74e-05	0.000191	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EDN1—systemic scleroderma	7.72e-05	0.00019	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CTLA4—systemic scleroderma	7.72e-05	0.00019	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RHOB—systemic scleroderma	7.69e-05	0.000189	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—MMP2—systemic scleroderma	7.68e-05	0.000189	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HSPG2—systemic scleroderma	7.64e-05	0.000188	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRF5—systemic scleroderma	7.63e-05	0.000188	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1A—systemic scleroderma	7.61e-05	0.000188	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD40LG—systemic scleroderma	7.57e-05	0.000186	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RHOB—systemic scleroderma	7.56e-05	0.000186	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SMAD7—systemic scleroderma	7.56e-05	0.000186	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—MMP2—systemic scleroderma	7.55e-05	0.000186	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRF8—systemic scleroderma	7.52e-05	0.000185	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ITGAM—systemic scleroderma	7.52e-05	0.000185	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD247—systemic scleroderma	7.52e-05	0.000185	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-DQB1—systemic scleroderma	7.5e-05	0.000185	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1A—systemic scleroderma	7.44e-05	0.000183	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD40LG—systemic scleroderma	7.39e-05	0.000182	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-DQB1—systemic scleroderma	7.39e-05	0.000182	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CSK—systemic scleroderma	7.38e-05	0.000182	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMAD7—systemic scleroderma	7.34e-05	0.000181	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	7.33e-05	0.000181	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—EDN1—systemic scleroderma	7.32e-05	0.00018	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRF8—systemic scleroderma	7.29e-05	0.00018	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ITGAM—systemic scleroderma	7.29e-05	0.00018	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD247—systemic scleroderma	7.29e-05	0.00018	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—RHOB—systemic scleroderma	7.28e-05	0.000179	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFBI—systemic scleroderma	7.26e-05	0.000179	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—TNFAIP3—systemic scleroderma	7.25e-05	0.000179	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HSPG2—systemic scleroderma	7.25e-05	0.000179	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—NOS3—systemic scleroderma	7.24e-05	0.000178	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—EDN1—systemic scleroderma	7.2e-05	0.000177	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BLK—systemic scleroderma	7.16e-05	0.000176	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—NOS3—systemic scleroderma	7.14e-05	0.000176	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HSPG2—systemic scleroderma	7.13e-05	0.000176	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMAD7—systemic scleroderma	7.12e-05	0.000175	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	7.11e-05	0.000175	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD40LG—systemic scleroderma	7.08e-05	0.000175	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—NOS3—systemic scleroderma	7.05e-05	0.000174	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—TNFAIP3—systemic scleroderma	7.04e-05	0.000173	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1A—systemic scleroderma	7.02e-05	0.000173	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CSK—systemic scleroderma	7e-05	0.000172	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD40LG—systemic scleroderma	6.98e-05	0.000172	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BLK—systemic scleroderma	6.95e-05	0.000171	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD247—systemic scleroderma	6.94e-05	0.000171	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	6.9e-05	0.00017	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CSK—systemic scleroderma	6.89e-05	0.00017	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—TNFAIP3—systemic scleroderma	6.83e-05	0.000168	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BLK—systemic scleroderma	6.75e-05	0.000166	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CCL2—systemic scleroderma	6.69e-05	0.000165	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EDN1—systemic scleroderma	6.64e-05	0.000164	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EDN1—systemic scleroderma	6.53e-05	0.000161	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TGFB1—systemic scleroderma	6.42e-05	0.000158	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-DQB1—systemic scleroderma	6.35e-05	0.000157	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CCL2—systemic scleroderma	6.29e-05	0.000155	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—CCL2—systemic scleroderma	6.26e-05	0.000154	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—NOS3—systemic scleroderma	6.07e-05	0.000149	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CSK—systemic scleroderma	6.06e-05	0.000149	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1A—systemic scleroderma	6.04e-05	0.000149	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MMP2—systemic scleroderma	6.02e-05	0.000148	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD40LG—systemic scleroderma	6e-05	0.000148	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—MMP9—systemic scleroderma	5.97e-05	0.000147	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—NOS3—systemic scleroderma	5.97e-05	0.000147	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRF5—systemic scleroderma	5.96e-05	0.000147	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTLA4—systemic scleroderma	5.87e-05	0.000145	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RHOB—systemic scleroderma	5.85e-05	0.000144	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HSPG2—systemic scleroderma	5.79e-05	0.000143	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—MMP9—systemic scleroderma	5.77e-05	0.000142	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTLA4—systemic scleroderma	5.7e-05	0.00014	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRF8—systemic scleroderma	5.7e-05	0.00014	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ITGAM—systemic scleroderma	5.7e-05	0.00014	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD247—systemic scleroderma	5.7e-05	0.00014	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CCL2—systemic scleroderma	5.69e-05	0.00014	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RHOB—systemic scleroderma	5.67e-05	0.00014	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—MMP9—systemic scleroderma	5.67e-05	0.00014	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP2—systemic scleroderma	5.67e-05	0.00014	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—NOS3—systemic scleroderma	5.61e-05	0.000138	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CSK—systemic scleroderma	5.59e-05	0.000138	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMAD7—systemic scleroderma	5.56e-05	0.000137	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTLA4—systemic scleroderma	5.52e-05	0.000136	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HSPG2—systemic scleroderma	5.51e-05	0.000136	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RHOB—systemic scleroderma	5.5e-05	0.000136	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—MMP1—systemic scleroderma	5.44e-05	0.000134	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TGFB1—systemic scleroderma	5.42e-05	0.000134	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EDN1—systemic scleroderma	5.41e-05	0.000133	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	5.39e-05	0.000133	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HSPG2—systemic scleroderma	5.35e-05	0.000132	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TNFAIP3—systemic scleroderma	5.33e-05	0.000131	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CSK—systemic scleroderma	5.32e-05	0.000131	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—TGFB1—systemic scleroderma	5.3e-05	0.00013	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—CCL2—systemic scleroderma	5.28e-05	0.00013	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BLK—systemic scleroderma	5.27e-05	0.00013	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD247—systemic scleroderma	5.26e-05	0.00013	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HSPG2—systemic scleroderma	5.19e-05	0.000128	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CSK—systemic scleroderma	5.17e-05	0.000127	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NOS3—systemic scleroderma	5.07e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	5.06e-05	0.000125	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CSK—systemic scleroderma	5.01e-05	0.000123	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EDN1—systemic scleroderma	4.9e-05	0.000121	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-DQB1—systemic scleroderma	4.83e-05	0.000119	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—TGFB1—systemic scleroderma	4.79e-05	0.000118	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MMP9—systemic scleroderma	4.79e-05	0.000118	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TGFB1—systemic scleroderma	4.75e-05	0.000117	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NOS3—systemic scleroderma	4.7e-05	0.000116	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-DQB1—systemic scleroderma	4.69e-05	0.000116	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TGFB1—systemic scleroderma	4.68e-05	0.000115	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TGFB1—systemic scleroderma	4.66e-05	0.000115	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1A—systemic scleroderma	4.59e-05	0.000113	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD40LG—systemic scleroderma	4.56e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EDN1—systemic scleroderma	4.56e-05	0.000112	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-DQB1—systemic scleroderma	4.55e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CCL2—systemic scleroderma	4.54e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MMP9—systemic scleroderma	4.52e-05	0.000111	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MMP9—systemic scleroderma	4.5e-05	0.000111	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CCL2—systemic scleroderma	4.47e-05	0.00011	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1A—systemic scleroderma	4.46e-05	0.00011	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD40LG—systemic scleroderma	4.43e-05	0.000109	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1B—systemic scleroderma	4.33e-05	0.000107	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1A—systemic scleroderma	4.32e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTLA4—systemic scleroderma	4.32e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RHOB—systemic scleroderma	4.3e-05	0.000106	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD40LG—systemic scleroderma	4.3e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP2—systemic scleroderma	4.29e-05	0.000106	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP9—systemic scleroderma	4.26e-05	0.000105	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—EDN1—systemic scleroderma	4.09e-05	0.000101	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MMP9—systemic scleroderma	4.07e-05	0.0001	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HSPG2—systemic scleroderma	4.06e-05	9.99e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1B—systemic scleroderma	3.97e-05	9.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NOS3—systemic scleroderma	3.95e-05	9.72e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TGFB1—systemic scleroderma	3.95e-05	9.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EDN1—systemic scleroderma	3.92e-05	9.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CSK—systemic scleroderma	3.92e-05	9.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1B—systemic scleroderma	3.88e-05	9.55e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EDN1—systemic scleroderma	3.86e-05	9.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EDN1—systemic scleroderma	3.72e-05	9.16e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TGFB1—systemic scleroderma	3.71e-05	9.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCL2—systemic scleroderma	3.7e-05	9.1e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1B—systemic scleroderma	3.66e-05	9.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DQB1—systemic scleroderma	3.55e-05	8.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TGFB1—systemic scleroderma	3.51e-05	8.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NOS3—systemic scleroderma	3.41e-05	8.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1A—systemic scleroderma	3.38e-05	8.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD40LG—systemic scleroderma	3.36e-05	8.27e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TGFB1—systemic scleroderma	3.35e-05	8.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CCL2—systemic scleroderma	3.35e-05	8.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NOS3—systemic scleroderma	3.29e-05	8.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP9—systemic scleroderma	3.23e-05	7.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—systemic scleroderma	3.15e-05	7.75e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCL2—systemic scleroderma	3.12e-05	7.68e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—TGFB1—systemic scleroderma	3.11e-05	7.66e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EDN1—systemic scleroderma	2.98e-05	7.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EDN1—systemic scleroderma	2.9e-05	7.14e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EDN1—systemic scleroderma	2.81e-05	6.92e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NOS3—systemic scleroderma	2.78e-05	6.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCL2—systemic scleroderma	2.68e-05	6.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TGFB1—systemic scleroderma	2.66e-05	6.55e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—systemic scleroderma	2.64e-05	6.51e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL2—systemic scleroderma	2.64e-05	6.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TGFB1—systemic scleroderma	2.61e-05	6.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL2—systemic scleroderma	2.54e-05	6.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS3—systemic scleroderma	2.52e-05	6.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—systemic scleroderma	2.39e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOS3—systemic scleroderma	2.39e-05	5.89e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOS3—systemic scleroderma	2.35e-05	5.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—systemic scleroderma	2.32e-05	5.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—systemic scleroderma	2.26e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—systemic scleroderma	2.25e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—systemic scleroderma	2.23e-05	5.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EDN1—systemic scleroderma	2.2e-05	5.41e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—systemic scleroderma	2.18e-05	5.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—systemic scleroderma	2.04e-05	5.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—systemic scleroderma	1.98e-05	4.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—systemic scleroderma	1.92e-05	4.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—systemic scleroderma	1.92e-05	4.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—systemic scleroderma	1.91e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—systemic scleroderma	1.89e-05	4.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—systemic scleroderma	1.84e-05	4.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—systemic scleroderma	1.82e-05	4.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—systemic scleroderma	1.77e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—systemic scleroderma	1.76e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—systemic scleroderma	1.71e-05	4.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—systemic scleroderma	1.67e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—systemic scleroderma	1.58e-05	3.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—systemic scleroderma	1.56e-05	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—systemic scleroderma	1.5e-05	3.7e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—systemic scleroderma	1.46e-05	3.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—systemic scleroderma	1.42e-05	3.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—systemic scleroderma	1.37e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.37e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—systemic scleroderma	1.34e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—systemic scleroderma	1.26e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—systemic scleroderma	1.2e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—systemic scleroderma	1.17e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—systemic scleroderma	1.13e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—systemic scleroderma	1.07e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.04e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—systemic scleroderma	8.85e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	4.52e-06	1.11e-05	CbGpPWpGaD
